FDA classifies the Spinal Muscular Atrophy (SMA) newborn screening test into Class II — supporting early-detection devices

Per the Federal Register (rule, published June 11, 2026), the FDA (U.S. Food and Drug Administration) classifies the spinal muscular atrophy (SMA) newborn screening test system into device Class II (special controls).

Spinal muscular atrophy (SMA) is a serious inherited neuromuscular disease in which motor neurons are affected and muscle strength declines. Newborn screening — testing newborns to detect serious conditions early — that catches SMA early can allow treatment to begin before symptoms appear, which can greatly improve outcomes. This rule concerns the test system used for that SMA newborn screening.

FDA medical devices are divided by risk into Class I (low risk, general controls), Class II (moderate risk, special controls), and Class III (high risk, premarket approval). This order classifies the SMA test system into Class II and sets out the "special controls" that apply to the device type, which become part of the codified classification language.

Per the abstract, the FDA is taking this action because it determined that Class II will provide a reasonable assurance of the device's safety and effectiveness. The FDA also states the action will enhance patients' access to beneficial, innovative devices, in part by reducing regulatory burden.

Why it matters: newborn screening is a cornerstone of public health, finding treatable serious diseases before they manifest. SMA is a leading example where early treatment matters greatly, and giving its test device a clear regulatory pathway (Class II plus special controls) can improve the outlook for adoption and new entrants. It is an example of regulatory groundwork in a field directly affecting patients and families — early detection of a serious genetic disease. Verify the latest, exact content at the source.